ViiV Archives -

The FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the

ViiV/J&J’s long-acting HIV regimen finally approved in US

https://pharmaphorum.com/news/fda-finally-approves-viiv-jjs-long-acting-hiv-regimen/

Digital/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

How to make digital adoption a smooth journey

George Underwood Bayer, commercial, comms, Digital Summit, GSK, Novo Nordisk, ViiV 0 Comment

Four big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely

How to make digital adoption a smooth journey

https://pharmaphorum.com/views-analysis-sales-marketing/digital-adoption-smooth-journey/

News/ News/ R&D

ViiV’s injection still suppresses HIV when taken every two months – study

Richard Staines HIV, infectious diseases, ViiV 0 Comment

GSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus

ViiV’s injection still suppresses HIV when taken every two months – study

https://pharmaphorum.com/news/viivs-injection-still-suppresses-hiv-when-taken-every-two-months-study/

News/ News/ R&D/ Top stories

ViiV hails data showing switch from Truvada to two-drug HIV regimen

Richard Staines Gilead, HIV, ViiV 0 Comment

ViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors

ViiV hails data showing switch from Truvada to two-drug HIV regimen

https://pharmaphorum.com/news/viiv-hails-data-showing-switch-from-truvada-to-two-drug-hiv-regimen/

News

ViiV’s Dovato HIV pill approved in EU

Richard Staines GlaxoSmithKline, HIV, infectious diseases, Pfizer, Shionogi, ViiV 0 Comment

ViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over

ViiV’s Dovato HIV pill approved in EU

https://pharmaphorum.com/news/viivs-dovato-hiv-pill-approved-in-eu/

Market Access/ News/ News

ViiV hopes for blockbuster with HIV drug combo approval

George Underwood Dovato, Gilead, HIV, ViiV 0 Comment

The FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for

ViiV hopes for blockbuster with HIV drug combo approval

https://pharmaphorum.com/news/viiv-hopes-blockbuster-hiv-drug-combo-approval/

R&D/ Views & Analysis/ Views and analysis

R&D round-up: Non-opioid painkiller space heats up

George Underwood Eli Lilly, Gilead, HIV, Janssen, Merck, MSD, NASH, opioid, pain, Pfizer, R&D, ViiV 0 Comment

As the MHRA announced that it would be convening an Expert Working Group (EWG) to assess the risks

R&D round-up: Non-opioid painkiller space heats up

https://pharmaphorum.com/views-and-analysis/rd-roundup-non-opioid-painkiller-space-heats-up/

News/ News/ R&D

Once-a-month HIV treatment sees promising phase III results

George Underwood Gilead, HIV, J&J, Janssen, ViiV 0 Comment

Janssen and ViiV have reported positive data for their once-monthly injectable HIV combo regimen in two phase III

Once-a-month HIV treatment sees promising phase III results

https://pharmaphorum.com/news/once-a-month-hiv-treatment-sees-promising-phase-iii-results/

News

ViiV redeems voucher for fast FDA review of HIV combination

Richard Staines HIV, infectious diseases, regulation, ViiV 0 Comment

ViiV Healthcare has applied for a fast US review of its single-tablet, two drug HIV drug regimen of

ViiV redeems voucher for fast FDA review of HIV combination

https://pharmaphorum.com/news/viiv-redeems-voucher-for-fast-fda-review-of-hiv-combination/

Trending

ViiV

Login